Charles Pauling Semba - 01 Jun 2025 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: Director
Signature: /s/ Scott Kellen, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 01 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Jun 2025, 16:18:43 UTC
Previous filing: 03 Jan 2025
Next filing: 06 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Semba Charles Pauling	Director	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS	/s/ Scott Kellen, attorney-in-fact	03 Jun 2025	0001872863

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DMAC	Voting Common Shares, no par value per share						44,608	01 Jun 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+32,162		$0.000000	32,162	01 Jun 2025	Common Shares	32,162	$4.11	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 3,967 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan.
F2	Vests in four nearly equal quarterly installments over one year.